Compare PROV & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROV | STRO |
|---|---|---|
| Founded | 1956 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.1M | 94.9M |
| IPO Year | 1996 | 2018 |
| Metric | PROV | STRO |
|---|---|---|
| Price | $15.38 | $8.66 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 7 |
| Target Price | $16.25 | ★ $19.67 |
| AVG Volume (30 Days) | 5.9K | ★ 99.8K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | $39,823,000.00 | ★ $105,646,000.00 |
| Revenue This Year | $4.14 | $62.61 |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | $17.06 | ★ N/A |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $12.98 | $5.23 |
| 52 Week High | $16.70 | $30.10 |
| Indicator | PROV | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 47.02 | 88.27 |
| Support Level | $15.01 | $0.72 |
| Resistance Level | $15.65 | $9.38 |
| Average True Range (ATR) | 0.41 | 0.38 |
| MACD | 0.03 | 0.95 |
| Stochastic Oscillator | 34.07 | 92.10 |
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.